eligibility_summary
Inclusion: Age 2–30 (first 3: 12–30), incurable recurrent/progressive solid tumor post required standard therapy, measurable/evaluable disease, archival tissue or biopsy for B7‑H3 (positivity not required), adequate performance status and organ function, prior therapy washouts, contraception/consent. Exclusion: other trials, recent other malignancy, untreated brain mets, uncontrolled infection, active HIV/HBV/HCV, major cardiac disease, pregnancy/breastfeeding, autoimmune on immunosuppression, systemic steroids, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Autologous B7-H3 CAR T cells (B7-H3CART), an engineered T‑cell therapy infused IV after lymphodepletion. Mechanism: patient T cells are transduced to express a chimeric antigen receptor that binds B7‑H3 (CD276) on tumor cells, inducing CAR signaling, T‑cell activation, cytokine release, and perforin/granzyme‑mediated cytotoxic killing independent of MHC. Dosing (3+3): 0.3–9×10^6 CAR+ T cells/kg. Lymphodepletion drugs: fludarabine (antimetabolite/purine analog) and cyclophosphamide (alkylating agent) to deplete lymphocytes and promote CAR‑T expansion/persistence. Targets: B7‑H3–expressing malignant cells in relapsed/refractory pediatric and young adult solid tumors (e.g., neuroblastoma, sarcomas, osteosarcoma). Key pathways/cells: B7 family antigen recognition, CAR/TCR signaling in autologous T cells.